SCHEMBL698739

SCHEMBL698739

OCCSc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
ALDH1A1 P00352 5/20 0.56
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA13 Q8N1Q1 1/20 0.52
TEAD1 P28347 1/20 0.52
YAP1 P46937 1/20 0.52
TEAD4 Q15561 1/20 0.52
TEAD2 Q15562 1/20 0.52
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7996868 0.94 KDM4E (0.51) KDM4EALDH1A1CA12CA1CA2
SCHEMBL11540114 0.88 KDM4E (0.47) KDM4EALDH1A1CA12CA1CA2
SCHEMBL8637757 0.87 CA2 (0.61) KDM4EALDH1A1CA12CA1CA2
SCHEMBL9808062 0.85 TEAD1 (0.53) KDM4EALDH1A1TEAD1YAP1TEAD4
SCHEMBL10916274 0.85 KDM4E (0.59) KDM4EALDH1A1CA2TEAD1YAP1
SCHEMBL8955502 0.83 HDAC3 (0.58) KDM4EALDH1A1CA2TEAD1YAP1
SCHEMBL26116458 0.83 HDAC3 (0.58) KDM4EALDH1A1CA2TEAD1YAP1
SCHEMBL7018220 0.81 CYP2A6 (0.43) KDM4EALDH1A1CA12CA1CA2
SCHEMBL3900894 0.80 CA2 (0.55) KDM4EALDH1A1CA12CA1CA2
SCHEMBL9808069 0.80 KDM4E (0.55) KDM4EALDH1A1TEAD1YAP1TEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-58079970-A None JP disclosed
CN-122039074-A Method for preparing sulfoxide compound by electrochemical microchannel continuous flow oxidation 南京工业大学 2026-05-15 CN disclosed
US-9657024-B2 Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival STATEGICS, INC. (US) 2017-05-23 US disclosed
EP-2185562-B1 PYRROLOPYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES JANSSEN PHARMACEUTICA NV (BE) 2015-12-02 EP disclosed
US-20150307498-A1 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2015-10-29 US disclosed
US-9163027-B2 Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival STATEGICS, INC. (US) 2015-10-20 US disclosed
EP-2922548-A2 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL Stategics, Inc. (US) 2015-09-30 EP disclosed
WO-2014081878-A2 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL STATEGICS, INC. (US) 2014-05-30 WO disclosed
US-20140142122-A1 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL STATEGICS, INC. (US) 2014-05-22 US disclosed
EP-2562167-A1 5-FLUORO PYRIMIDINE DERIVATIVES AS FUNGICIDES Dow AgroSciences LLC (US) 2013-02-27 EP disclosed
WO-2000023071-A9 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS LEUKOSITE INC (US) 2000-09-14 WO disclosed
WO-2000023071-A1 PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS LEUKOSITE, INC. (US) 2000-04-27 WO disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed
US-5141552-A Applying isothiazole plant growth regulator to one variety, pollinating with another UNIVERSITY PATENTS, INC. (US) 1992-08-25 US disclosed
US-4937268-A TREATMENT OF ASTHMA, CHRONIC BRONCHITIS GLAXO GROUP LIMITED (GB) 1990-06-26 US disclosed
EP-0286242-A2 Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 1988-10-12 EP disclosed
JP-S5879970-A PROPIOLIC ACID ESTER IHARA CHEM IND CO LTD 1983-05-13 JP disclosed
US-4000315-A Cyclopropane esters for the control of mites ZOECON CORPORATION (US) 1976-12-28 US disclosed
US-3957849-A MITICIDES ZOECON CORPORATION (US) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142122-A1 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL EPOR, THPO, MKI67 KDM4E 2685/4885ALDH1A1 396/4885CA12 4827/4885
US-20150307498-A1 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL EPOR, THPO, MKI67 KDM4E 2685/4885ALDH1A1 396/4885CA12 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.